Protalex, Inc. (OTCBB: PRTX) is a biotechnology company developing a new class of drugs with the potential to revolutionize the treatment of autoimmune and inflammatory diseases, including Rheumatoid Arthritis (RA) and Immune Thrombocytopenia (ITP). Protalex’s lead product, PRTX-100, is a formulation of a proprietary, highly purified form of Staphylococcal Protein A, which is an immunomodulatory protein produced by bacteria. PRTX-100 has the ability, at very low concentrations, to bind to human B-lymphocytes and macrophages and to modulate immune processes. For more information, visit the company’s website atwww.protalex.com.